SAF score and mortality in NAFLD after up to 41 years of follow-up

Scandinavian Journal of Gastroenterology

Volumn 52, Issue 1, 2017, Pages 87-91

  Hagström, Hannes ^a,b   Nasr, Patrik ^c   Ekstedt, Mattias ^c   Kechagias, Stergios ^c   Stål, Per ^a,b   Bedossa, Pierre ^d   Hultcrantz, Rolf ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d BEAUJON HOSPITAL   (France)

Author keywords

fibrosis; mortality; NAFLD; NAS score; NASH; SAF score

Indexed keywords

ADULT; ARTICLE; BODY MASS; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; STEATOSIS, ACTIVITY, AND FIBROSIS SCORE; ALGORITHM; FIBROSIS; LIVER; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SWEDEN;

ADULT; ALGORITHMS; FEMALE; FIBROSIS; FOLLOW-UP STUDIES; HUMANS; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SWEDEN;

EID: 84986222780     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365521.2016.1230779     Document Type: Article

References (21)

1. Loomba R, Sanyal AJ., The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686–690.
2. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence and outcomes. Hepatology. 2015;64:73–84.
3. Vernon G, Baranova A, Younossi ZM., Systematic review:the epidemiology and natural history of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–285.
4. Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis:a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13:643–654. e1–9. quiz e39–40.
5. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis:a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–2474.
6. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.
7. Brunt EM, Kleiner DE, Wilson LA, et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD:distinct clinicopathologic meanings. Hepatology. 2011;53:810–820.
8. Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61:1547–1554.
9. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, associates with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389–397.
10. Stepanova M, Rafiq N, Makhlouf H, et al. Predictors of all-cause mortality and liver-related mortality in patients with nonalcoholic fatty liver disease (NAFLD). Digest Dis Sci. 2013;58:3017–3023.
11. Bedossa P, Poitou C, Veyrie N, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012;56:1751–1759.
12. Bedossa P., Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60:565–575.
13. Hultcrantz R, Glaumann H, Lindberg G, et al. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. Scand J Gastroenterol. 1986;21:109–113.
14. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–873.
15. Soderberg C, Stal P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51:595–602.
16. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, et al. The Swedish personal identity number:possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24:659–667.
17. Satapathy SK, Sanyal AJ., Epidemiology and natural history of nonalcoholic fatty liver disease. Semin Liver Dis. 2015;35:221–235.
18. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–555.
19. Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141:1249–1253.
20. Hardy T, Anstee QM, Day CP., Nonalcoholic fatty liver disease:new treatments. Curr Opin Gastroenterol. 2015;31:175–183.
21. Gawrieh S, Chalasani N., Pharmacotherapy for nonalcoholic fatty liver disease. Semin Liver Dis. 2015;35:338–348.